Abbott Laboratories

ABT

NYSE

126.85

USD

+0.51(+0.40%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Abbott Laboratories fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

15.94

Price/Book

4.37

Debt/Equity

26.57%

Return on Equity

29.93%

Dividend Yield

1.86%

EBITDA

10.83B

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	34,608,000,000	43,075,000,000	43,653,000,000	40,109,000,000	41,950,000,000
Gross Profit	17,377,000,000	23,214,000,000	22,323,000,000	20,037,000,000	21,325,000,000
Operating Income	5,291,000,000	9,200,000,000	8,362,000,000	6,435,000,000	6,825,000,000
Net Income	4,495,000,000	7,071,000,000	6,933,000,000	5,723,000,000	13,402,000,000
Total Assets	72,548,000,000	75,196,000,000	74,438,000,000	73,214,000,000	81,414,000,000
Total Current Liabilities	11,907,000,000	13,105,000,000	15,489,000,000	13,841,000,000	14,157,000,000
Total Equity	33,003,000,000	36,024,000,000	36,905,000,000	38,827,000,000	47,901,000,000
Free Cash Flow	5,724,000,000	8,648,000,000	7,804,000,000	5,059,000,000	6,351,000,000
Cash from Operations	7,901,000,000	10,533,000,000	9,581,000,000	7,261,000,000	8,558,000,000
Cash from Investing	-2,215,000,000	-2,008,000,000	-1,740,000,000	-3,133,000,000	-2,338,000,000
Cash from Financing	-2,779,000,000	-5,494,000,000	-7,636,000,000	-7,091,000,000	-5,404,000,000
Net Change in Cash	2,978,000,000	2,961,000,000	83,000,000	-2,986,000,000	720,000,000

Abbott Laboratories

ABT

126.85

Abbott Laboratories fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations